



PRESS RELEASE

Lunel, 5 July 2018

**SUCCESS OF BIO-UV GROUP INITIAL PUBLIC OFFERING
ON EURONEXT GROWTH
€10 MILLION RAISED**

- Offering oversubscribed 1.3 times
- 10 € million raised under the global placement and the open price offer (OPO) after full exercise of the extension clause, which may be increased to € 10.4 million in the event of exercise of the over-allotment option
- Final share price set at €3.84
- Start of trading on the Euronext Growth market on 10 July 2018

BIO-UV Group, a specialist in ultraviolet water treatment systems, announces the success of its initial public offering on the Euronext Growth market in Paris (ISIN code: FR0013345493/ Ticker: ALTUV).

In light of the demand, BIO-UV Group's Board of Directors today set the final share price at €3.84.

It also decided to exercise the extension clause in full, enabling BIO-UV Group to raise €10 million. This figure could increase to €10.4 million if the over-allotment option is exercised.

Total demand came to 2,833,265 shares, including 87% under the global placement (mainly intended for institutional investors) and 13% under the open price offer (mainly intended for individual investors), such that the offering was 1.3 times oversubscribed¹.

The number of shares allocated under the global placement stands at 2,321,430 new shares, representing a total of €8,9 million. 375,380 shares were allocated to the public under the open price offer, for an amount of €1.4 million. A1 and A2 orders will be 100% honoured.

The total number of shares issued following the full exercise of the extension clause stands at 2,610,810 new shares. On these bases and given the IPO price of €3.84 per share, BIO-UV Group has a market capitalisation of around €30 million.

¹ Based on the initial offering: global placement and open price offer, excluding the extension clause and over-allotment option.



PRESS RELEASE

Following this transaction, BIO-UV Group's share capital is composed of 7,789,295 shares. The company's free float accounts for 30.7% of its share capital before the possible exercise of the over-allotment option.

BIO-UV Group has granted Gilbert Dupont an over-allotment option, exercisable until 3 August 2018, for a maximum of 95,000 new shares, representing a maximum amount of approximately €0.4 million.

Settlement/delivery of the new shares issued under the global placement and the open price offer is scheduled for 09 July 2018. The shares will be admitted for continuous trading on the Euronext Growth market as from 10 July 2018, under the ISIN code: FR0013345493 and the ticker: ALTUV.

A liquidity contract will be implemented not later than the end of the stabilisation period, which will start on 10 July 2018 and end on 3 August 2018. Its implementation will be announced to the market in due course, in compliance with applicable legal and regulatory requirements.

On completion of the IPO, Benoît Gillmann, CEO and founder of BIO-UV Group, commented: "We are proud to announce the success of our initial public offering and would like to sincerely thank our reference shareholders (Soridec, Naxicap and ACE Management) for their support, as well as all the new shareholders, institutions and private individuals, who have put their faith in us. I would also like to extend my warmest thanks to all the loyal employees of BIO-UV Group, who, through their daily commitment, contribute to the company's success in France and abroad since nearly 20 years. The funds raised will allow us to accelerate our momentum and seize all opportunities that present themselves, both on our historical markets and the ballast water treatment market, which is set to see major growth."

Post-transaction breakdown of share ownership

Following the IPO, BIO-UV Group's share capital is distributed as follows:

Shareholders	Before issue of new shares		Non-diluted capital after issue of new shares and full exercise of Extension Clause			
	Number of shares	% of capital and voting rights	Number of shares	% of capital	Number of voting rights (1)	% of voting rights
EUURL BGH (2)	1,941,027	37.42%	1,967,068	25.25%	3,509,667	29.66%
Benoît Gillmann	661,863	12.76%	661,863	8.50%	1,323,726	11.19%
Subtotal Benoît Gillmann	2,602,890	50.18%	2,628,931	33.75%	4,833,393	40.84%
SCR Banque Populaire	725,000	13.98%	777,083	9.98%	1,502,083	12.69%
SAS Naxicap Rendement 2018	725,000	13.98%	725,000	9.31%	1,450,000	12.25%
Naxicap	1,450,000	27.95%	1,502,083	19.28%	2,952,083	24.95%
SORIDEC	390,564	7.53%	442,647	5.68%	833,211	7.04%
ATALAYA (3)	644,425	12.42%	696,508	8.94%	696,508	5.89%
Subtotal financial investors	2,484,989	47.90%	2,641,238	33.91%	4,481,802	37.87%
Xavier BAYLE	99,606	1.92%	99,606	1.28%	99,606	0.84%
Laurent-Emmanuel Migeon	0	0.00%	26,041	0.33%	26,041	0.22%
Subtotal employees	99,606	1.92%	125,647	1.61%	125,647	1.06%
Free float	0	0.00%	2,393,479	30.73%	2,393,479	20.22%
Total	5,187,485	100.00%	7,789,295	100.00%	11,834,321	100.00%



PRESS RELEASE

(1) Including the double voting rights granted on the day of listing on the Euronext Growth Paris market of the Company's shares.

(2) Company whose capital is wholly owned by Benoit GILLMANN, Chief Executive Officer of the Company.

(3) ATALAYA is a Professional Private Equity Fund, represented by its management company ACE MANAGEMENT.

Next steps in the transaction

09 July 2018	Settlement/delivery of new shares
10 July 2018	Start of trading on the Euronext Growth market in Paris
03 August 2018	Deadline for exercising the over-allotment option and end of possible stabilisation period

About BIO-UV GROUP

Created in 2000, BIO-UV Group designs, manufactures and markets innovative ultraviolet water treatment systems. The range of equipment developed by the Group is aimed at several markets:

- The recreation market, on which BIO-UV Group is no. 1 in France and in Europe for UV water treatment in residential swimming pools, and for the public and semi-public community pool de-chlorination market;
- The municipal and industrial markets, on which specific ranges have been developed for applications such as: purification, effluent treatment, wastewater reuse, process waters, aquaculture, etc.;
- The ballast water treatment market, which has benefited since 2017 from a new international regulation requiring all ships to have equipment to treat their ballast water.

In 2017, BIO-UV Group generated revenue of €10.2 million and EBITDA of €1.1 million, representing an EBITDA margin of 11.1%. As of 31 March 2018, the Group had 61 employees.

BIO-UV Group has been granted the "Innovative Company" label by Bpifrance and is eligible for the French "PEA-PME" investment scheme.

Contacts:

BIO-UV Group
+33 (0)4 99 13 39 11
invest@bio-uv.com

ACTIFIN, financial communications
Alexandre Commerot
+33 (0)1 56 88 11 11
biouv@actifin.fr

ACTIFIN, financial press relations
Isabelle Dray
+33 (0)1 56 88 11 29
idray@actifin.fr

MAIN CHARACTERISTICS OF THE OFFER

Offer price

The price of the open price offer and of the global placement is set at €3.84 per share.

Size of and gross proceeds from the offering

2,601,810 new shares were issued under the offering after full exercise of the extension clause and before possible exercise of the over-allotment option. Total gross proceeds from the issue stand at €10 million after the full exercise of the extension clause and before the possible exercise of the over-allotment option.

BIO-UV Group has granted Gilbert Dupont an over-allotment option, exercisable from 10 July 2018 to 3 August 2018 2018 (inclusive), for a maximum of 95,000 new shares, or a maximum amount of €0.4 million.

Allotment of the offer

- Global placement: 2,321,430 shares were allocated to institutional investors, or €8.9 million and approximately 86 % of the total shares offered;
- Open price offering: 375,380 shares were allocated to the public, or €1.4 million and approximately 14 % of the total shares offered (i.e. 17 % of the initial offer before extension clause). A1 and A2 orders will be 100% honoured.

The Company's lock up commitment and shareholder retention commitments

- Company's lock-up agreement: 180 days from the date of settlement/delivery of the new shares;
- Lock-up agreement applicable to all shareholders: 360 days from the date of settlement/delivery of the new shares.

Transaction partners



GROUPE SOCIÉTÉ GÉNÉRALE



Listing Sponsor, Lead Arranger and Bookrunner

Company Advisor

Legal advisor

Financial Communication

Statutory Auditor

Characteristics of the shares

- Name: BIO-UV GROUP
- Ticker: ALTUV
- ISIN code: FR0013345493
- Listing market: Euronext Growth Paris
- ICB Classification: 2757 Industrial Machinery
- Eligible for PEA-PME and BPI Innovative Company qualification²

Availability of the Prospectus

Copies of the Prospectus, registered by the AMF on 22 June 2018 under number 18-255, are available free of charge on request from the registered office of BIO-UV Group (850 avenue Louis Médard, 34400 Lunel) and on the websites of the AMF (www.amf-france.org) and the Company (investir.bio-uv.com).

Risk factors

Any investment in shares entails some risk. The attention of investors is drawn to Chapter 4 "Risk Factors" of Part One of the Prospectus approved by the AMF.

² These mechanisms are conditional and subject to the limit of available caps. Interested parties should contact their financial advisor.



Disclaimer

This press release and the information contained herein do not, and shall not, in any circumstances constitute an offer to sell or purchase, or the solicitation of an offer to sell or purchase BIO-UV Group shares in any country.

The dissemination, publication or distribution of this press release may, in some countries, be subject to specific regulations. As a result, persons physically present in these countries and in which the press release is disseminated, published or distributed must inform themselves and comply with these laws and regulations.

This press release constitutes a communication of a promotional nature and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003 (as transposed in each of the Member States of the economic Area European Union) (the "Prospectus Directive").

This document is not an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States of America. BIO-UV Group shares or other securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or an exemption from registration. The shares of the company BIO-UV Group will be offered or sold only outside the United States of America and in the context of offshore transactions, in accordance with Regulation S of the Securities Act. Bio-UV Group does not intend to register the offer in whole or in part in the United States of America or to make an offer to the public in the United States of America.

With respect to the member States of the European Economic Area, which have implemented the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in the context of a public offering in any relevant member State other than France. As a result, the BIO-UV Group shares may not and will not be offered in any relevant member State other than France except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member State, or under any other circumstances which do not require the publication by BIO-UV Group of a prospectus in the context of a public offering pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member State.

With respect to England, this press release is only being distributed to, and is only directed at persons (i) who are not in the United Kingdom, (ii) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (iii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated directly or indirectly (all such persons together being referred to as "Relevant Persons").

This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons.

This press release provides guidance on the objectives of BIO-UV Group and contains prospective statements. This information is not historical data and should not be construed as a guarantee that the facts and data set out will occur. This information is based on data, assumptions and estimates considered reasonable by BIO-UV Group. The latter operates in a competitive and rapidly evolving environment. Therefore, BIO-UV Group is not in a position to anticipate all risks, uncertainties or other factors likely to affect its activity, their potential impact on its activity, or to what extent the



PRESS RELEASE

materialization of a risk or combination of risks could have significantly different results from those mentioned in any prospective statements. This information is only given on the date of this press release. BIO-UV Group makes no commitment to publish updates to this information or the assumptions on which it is based, with the exception of any legal or regulatory obligation applicable to it.

No copy of this press release is, and shall be, distributed or sent directly or indirectly to the United States of America, Canada, Japan or Australia.